Cargando…
NT‐proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trials
AIMS: Heart failure (HF) and atrial fibrillation (AF) frequently coexist and are both associated with increased levels of N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP). It is known that AF impairs the diagnostic accuracy of NT‐proBNP for HF. The aim of the present study was to compare the di...
Autores principales: | Werhahn, Stefanie M., Becker, Christian, Mende, Meinhard, Haarmann, Helge, Nolte, Kathleen, Laufs, Ulrich, Zeynalova, Samira, Löffler, Markus, Dagres, Nikolaos, Husser, Daniela, Dörr, Marcus, Gross, Stefan, Felix, Stephan B., Petersmann, Astrid, Herrmann‐Lingen, Christoph, Binder, Lutz, Scherer, Martin, Hasenfuß, Gerd, Pieske, Burkert, Edelmann, Frank, Wachter, Rolf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788004/ https://www.ncbi.nlm.nih.gov/pubmed/34850596 http://dx.doi.org/10.1002/ehf2.13703 |
Ejemplares similares
-
NT-proBNP and diastolic left ventricular function in patients with Marfan syndrome
por: Gehle, Petra, et al.
Publicado: (2016) -
Die Biomarker BNP und NT‑proBNP
por: Oremek, G. M., et al.
Publicado: (2023) -
Outcome assessment using estimation of left ventricular filling pressure in asymptomatic patients at risk for heart failure with preserved ejection fraction
por: Bobenko, Anna, et al.
Publicado: (2020) -
The diagnostic and prognostic value of galectin‐3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST‐CHF study
por: Trippel, Tobias Daniel, et al.
Publicado: (2021) -
Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial
por: Senni, Michele, et al.
Publicado: (2022)